Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections

Ls, Shan; Hou, Ping; Zj, Wang; Fr, Liu; Chen, N; Lh, Shu; Zhang, H; Xh, Han; Han, Xinwei; Xx, Cai; Yx, Shang; Vandenplas, Yvan

doi:10.3920/bm2013.0008

Cited by 61 publications

(54 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although some studies demonstrated the effectiveness of S. boulardii for resetting alterations caused by antibiotic treatment [37,38,39], we found no microbial protective effects in this study; the results of the group that received S. boulardii were identical to those of the group that received amoxicillin alone (i.e. an increase in body fat was observed).…”

Section: Discussionsupporting

confidence: 47%

Obesity and the Use of Antibiotics and Probiotics in Rats

et al. 2014

View full text Add to dashboard Cite

Background: Obesity has become a major public health challenge in recent years. Recent studies suggest that alterations of the gut microbiota by antibiotics could play an important role in obesity. Methods: We investigated this topic using 60 Wistar rats, which were divided into 3 experimental groups: rats treated with amoxicillin, rats treated with amoxicillin plus Saccharomyces boulardii and controls. Treatments were administered over the course of 2 weeks. Tetrapolar bioelectric impedance analysis and anthropometric evaluations were conducted. Results: The body mass index was significantly lower for the animals in the control group (p = 0.034). The same result was observed for the Lee index: the control group had a lower index than the 2 groups that received antibiotic treatment (p = 0.0019). The total body water data demonstrated that the control group had the greatest amount of body water (279.1 g, p = 0.0243). Conclusions: The groups treated with the antibiotic exhibited a greater accumulation of body fat than the control group.

show abstract

Section: Discussionsupporting

confidence: 47%

Obesity and the Use of Antibiotics and Probiotics in Rats

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Most reports show a clinical benefit of S. boulardii in decreasing the duration of diarrhoea regardless of the cause and thus reducing hospital stay resulting in social and economic benefits [7,33,56,57,58]. Administration of S. boulardii has shown positive effects for patients with irritable bowel syndrome [59], preventing and treating relapses of inflammatory bowel disease and for treating moderate symptoms of ulcerative colitis [60,61].…”

Section: Resultsmentioning

confidence: 99%

Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature

Fijan

2014

IJERPH

817

455

View full text Add to dashboard Cite

Probiotics are defined as live microorganisms, which when administered in adequate amounts, confer a health benefit on the host. Health benefits have mainly been demonstrated for specific probiotic strains of the following genera: Lactobacillus, Bifidobacterium, Saccharomyces, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus, Escherichia coli. The human microbiota is getting a lot of attention today and research has already demonstrated that alteration of this microbiota may have far-reaching consequences. One of the possible routes for correcting dysbiosis is by consuming probiotics. The credibility of specific health claims of probiotics and their safety must be established through science-based clinical studies. This overview summarizes the most commonly used probiotic microorganisms and their demonstrated health claims. As probiotic properties have been shown to be strain specific, accurate identification of particular strains is also very important. On the other hand, it is also demonstrated that the use of various probiotics for immunocompromised patients or patients with a leaky gut has also yielded infections, sepsis, fungemia, bacteraemia. Although the vast majority of probiotics that are used today are generally regarded as safe and beneficial for healthy individuals, caution in selecting and monitoring of probiotics for patients is needed and complete consideration of risk-benefit ratio before prescribing is recommended.

show abstract

“…Figure S1 documents the identification process for eligible trials. In addition to the previously identified five RCTs, 16 new trials were included . Except for three trials published in Chinese, Portuguese and Spanish for which the translation was obtained, all of the remaining trials were published in English.…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea

Szajewska

Kołodziej

2015

Aliment Pharmacol Ther

171

View full text Add to dashboard Cite

Summary Background Antibiotic‐associated diarrhoea is a common complication of antibiotic use, but it can be prevented with administration of probiotics. Aim To update our 2005 meta‐analysis on the effectiveness of Saccharomyces boulardii in preventing antibiotic‐associated diarrhoea in children and adults. Methods The Cochrane Library, MEDLINE, and EMBASE databases were searched up until May 2015, with no language restrictions, for randomised controlled trials; additional references were obtained from reviewed articles. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Results Twenty‐one randomised controlled trials (4780 participants), among which 16 were new trials, met the inclusion criteria for this updated systematic review. Administration of S. boulardii compared with placebo or no treatment reduced the risk of antibiotic‐associated diarrhoea (as defined by the study investigators) in patients treated with antibiotics from 18.7% to 8.5% (risk ratio, RR: 0.47; 95% CI: 0.38–0.57, number needed to treat, NNT: 10; 95% CI: 9–13). In children, S. boulardii reduced the risk from 20.9% to 8.8% (6 randomised controlled trials, n=1653, RR: 0.43, 95% CI: 0.3–0.6); in adults, from 17.4% to 8.2% (15 randomised controlled trials, n=3114, RR: 0.49, 95% CI: 0.38–0.63). Moreover, S. boulardii reduced the risk of Clostridium difficile‐associated diarrhoea; however, this reduction was significant only in children (2 randomised controlled trials, n = 579, RR: 0.25; 95% CI: 0.08–0.73) and not in adults (9 randomised controlled trials, n = 1441, RR: 0.8, 95% CI: 0.47–1.34). Conclusions This meta‐analysis confirms that S. boulardii is effective in reducing the risk of antibiotic‐associated diarrhoea in children and adults.

show abstract

Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections

Cited by 61 publications

References 21 publications

Obesity and the Use of Antibiotics and Probiotics in Rats

Obesity and the Use of Antibiotics and Probiotics in Rats

Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature

Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea

Contact Info

Product

Resources

About